NASDAQ:ELAB

Elevai Labs . Common Stock Stock News

Healthcare > Biotechnology

Buy ELAB

*Your capital is at risk

$1.32

-0.0300 (-2.22%)

At Close: Jun 23, 2026

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

09:54am, Tuesday, 22'nd Oct 2024

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Dr

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by